LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report) today and set a price target of $44.00.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rami Katkhuda’s rating is based on the positive topline results from Mineralys Therapeutics, Inc.’s Phase II Explore-CKD study. The study evaluated the effects of lorundrostat, an aldosterone synthase inhibitor, in combination with other treatments in patients with hypertension and chronic kidney disease (CKD). The results showed a significant reduction in systolic blood pressure and a notable decrease in urinary albumin-to-creatinine ratio, indicating potential renal protection.
Furthermore, lorundrostat was generally well-tolerated among patients, even those with impaired renal function. The manageable changes in potassium levels and the absence of significant adverse effects contribute to the positive outlook. These factors, combined with the promising efficacy and safety profile of lorundrostat, underpin Katkhuda’s Buy rating for Mineralys Therapeutics, Inc.’s stock.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $42.00 price target.